MSL DAILY PHARMA NEWS - Epizyme announces US FDA accelerated approval of TAZVERIK for relapsed/refractory follicular lymphoma #Epizyme #Tazverik “Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for TAZVERIK™ (tazemetostat) for the following two distinct follicular lymphoma (FL) indications. Adult patients with relapsed or refractory FL whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies.” Free webinar on “how to become an MSL” https://lnkd.in/gFYBJ2G Or click on our profile. Click below to read further, like and share it and follow us to learn more. Our Medical Science Liaison testimonials: Http://https://lnkd.in/eEfHu4c #MSL #FSTP #MSLcert #medicalscienceliaison https://lnkd.in/eNB_Y-T https://www.instagram.com/p/CB91Tn_jwOj/?igshid=10x7zfab1ulsy
